- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00791908
Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata
The primary objective of this study is to determine whether laser treatments over 6 weeks using the pulsed dye laser system or the potassium titanyl phosphate (KTP) laser are effective in patients with cherry angiomas as observed by a physician provider and the subject.
The investigators hypothesize that the two laser treatments will be an effective tool for treating cherry angiomas. The investigators aim to compare these modalities to electrodessication, as all three modalities are considered the current standard of care. Electrodessication can result in atrophic lesions at the site of the treated cherry angiomas.
In summary, the goal of this project is to compare the non-ablative pulsed dye laser and the AuraTM potassium titanyl phosphate (KTP) laser to each other and to the current standard of care, electrodessication.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 95 years.
- Have at least 12 cherry angiomas (4 per each third of the torso) that have been documented.
- The subjects are in medically stable condition.
- The subject has willingness and the ability to understand and provide informed consent for the procedure and is able to communicate with the investigator.
- Must be willing not to employ other treatment options for cherry angiomas during the course of this study.
Exclusion Criteria:
- Under 18 years of age and over 95 years of age
- Pregnancy or lactation.
- Subjects who are unable to understand the protocol or to give informed consent.
- Subjects cannot have had previous laser treatment in the last 6 months before enrollment.
- Subjects have a cardiac defibrillator or pacemakers that may interact with the electrodesiccation technique.
- Subjects have no serious medical conditions that would contradict participation in the research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: electrodessication (ED)
Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas.
Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
|
Treatment applied to a third of the torso at each study visit.
|
|
Experimental: pulsed dye laser (PDL)
Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas.
Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
|
Laser treatment applied to a third of the torso at each study visit.
|
|
Experimental: potassium titanyl phosphate (KTP) laser
Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas.
Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
|
Laser treatment applied to a third of the torso at each study visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Changes in Color, Texture, and Size of Cherry Angiomata From Baseline to 3 Months After the Second Treatment by Treatment Type as Assessed by Blinded Raters
Time Frame: Baseline and 3 months
|
Each subject received all 3 treatments.
Serial standardized photographs evaluated for color,texture and size by 2 blinded dermatologists using ordinal visual analog scales from 0 to 10(color: 0=skin colored, 5=red, 10=purple; texture: 0=flat, 5=mildly elevated, 10=elevated; size: 0=0mm, 10=10 mm).
|
Baseline and 3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MA-STU81
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cherry Angioma
-
Cutera Inc.Completed
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
Université de SousseSahloul Hospital of SousseCompletedLiver Angioma
-
West China HospitalRecruitingTacrolimus, Kaposiform Hemangioendothelioma, Tufted AngiomaChina
-
Hospices Civils de LyonNot yet recruiting
-
Boston Children's HospitalPfizerTerminatedKasabach-Merritt Syndrome | Tufted Angioma | Kaposiform Hemangioendothelioma (KHE)United States
-
University of ChicagoMayo Clinic; National Institute of Neurological Disorders and Stroke (NINDS); University of California, San Francisco and other collaboratorsActive, not recruitingCerebral Cavernous Malformation | Cavernous Angioma | Hemorrhagic MicroangiopathyUnited States
-
Denise Martin AdamsChildren's Hospital Medical Center, CincinnatiCompletedTufted Angioma | Microcystic Lymphatic Malformation | Kaposiform Hemangioendotheliomas | Capillary Venous Lymphatic Malformation | Venous Lymphatic Malformation | Mucocutaneous Lymphangiomatosis and Thrombocytopenia | Capillary Lymphatic Arterial Venous Malformations | PTEN Overgrowth Syndrome With... and other conditionsUnited States
-
Boston Children's HospitalLymphatic Malformation InstituteRecruitingLymphangiomatosis | Kaposiform Lymphangiomatosis | Lymphatic Malformation | Generalized Lymphatic Anomaly (GLA) | Central Conducting Lymphatic Anomaly | CLOVES Syndrome | Gorham-Stout Disease ("Disappearing Bone Disease") | Blue Rubber Bleb Nevus Syndrome | Kaposiform Hemangioendothelioma/Tufted Angioma and other conditionsUnited States
-
University of ChicagoJohns Hopkins University; Mayo Clinic; National Institute of Neurological Disorders... and other collaboratorsCompletedCerebral Cavernous Malformation | Cavernous Angioma | Cavernoma | CCM | Cerebral Cavernous Malformations 1 | Cerebral Cavernous Malformations 2 | Cerebral Cavernous Malformations 3United States
Clinical Trials on Electrodessication
-
University of Wisconsin, MadisonDermatology Foundation; Skin Cancer FoundationTerminatedSuperficial Basal Cell CarcinomaUnited States
-
Northwestern UniversityNot yet recruitingSebaceous HyperplasiaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Not yet recruitingBasal Cell Carcinoma | Squamous Cell Carcinoma | Nonmelanoma Skin CancerUnited States